Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients

This study has been withdrawn prior to enrollment.
(Site did not recruit any patients)
Information provided by:
Meditor Pharmaceuticals Ltd. Identifier:
First received: June 1, 2007
Last updated: April 6, 2015
Last verified: April 2015
The purpose of this study is to evaluate the safety, pharmacokinetic and the pharmacodynamic effects of escalating doses of MTR105 while weaning from bypass in a hypotensive population of cardiac surgery patients.

Condition Intervention Phase
Cardiopulmonary Bypass
Drug: MTR105
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study to Assess the Pharmacokinetics and Pharmacodynamics of MTR105 in Cardiac Surgery Induced Hypotension Patients During Weaning Off Cardiopulmonary Bypass

Resource links provided by NLM:

Further study details as provided by Meditor Pharmaceuticals Ltd.:

Primary Outcome Measures:
  • Hemodynamic parameters [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Pharmacokinetics [ Time Frame: 10 hours ]

Enrollment: 0
Study Start Date: January 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Dose level 0.3 mg/kg with 6 active and 2 placebo
Drug: MTR105
Intravenous administration, dose escalating (4 arms), single dose
Dose level 0.6 mg/kg 6 patients active and 2 placebo
Drug: MTR105
Intravenous administration, dose escalating (4 arms), single dose
Dose level 1.2 mg/kg 6 active and 2 placebo
Drug: MTR105
Intravenous administration, dose escalating (4 arms), single dose
Dose level 2.4 mg/kg 6 active and 2 placebo
Drug: MTR105
Intravenous administration, dose escalating (4 arms), single dose

Detailed Description:
The study is a prospective, randomized, four-arm, dose-escalating, double blind, placebo controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of four dose levels of MTR105 in patients undergoing cardiac surgery utilizing cardiopulmonary bypass presenting hypotension upon weaning off bypass.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women age 18 years or older
  • Referred for cardiac surgery requiring the use of CPB.
  • Elective or urgent surgeries (non emergency operations).
  • LVEF ≥40 based on cardiac catheterization results
  • Normal renal function at study entry
  • Normal hepatic function (within normal laboratory ranges) at study entry
  • Normal coagulation status at study entry as judged by PT, PTT, fibrinogen and platelet count.
  • Willingness to participate in the study and adhere to the study design.
  • Willingness to sign an informed consent form.

Exclusion Criteria:

  • Emergency operation
  • Pulmonary hypertension (PA systolic pressure >60 mmHg)
  • Ejection fraction less than 35% during weaning from bypass or cardiac index of less than 1.8
  • Neurological events such as prior CVA, TIA or symptomatic carotid stenosis within 1 year of presenting for surgery
  • Body weight <40 Kg
  • Pregnancy
  • Malignancy within 1 year of presenting for surgery
  • Systemic infection as evidenced by elevated WBC or fever >38.5 C
  • Usage of vasoactive medications within 24 hours except short term use of a vasoconstrictor during induction.
  • Participation in any other investigational drug or device study within 30 days of randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00482287

United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Meditor Pharmaceuticals Ltd.
Principal Investigator: Penny Sappington, MD University of Pittsburgh
  More Information

Responsible Party: Adrian Harel, Meditor Pharmaceuticals Ltd Identifier: NCT00482287     History of Changes
Other Study ID Numbers: MTR-105-US-102
Study First Received: June 1, 2007
Last Updated: April 6, 2015

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on May 25, 2017